• Patient Square Capital named Timothy P. Walbert senior advisor, expanding its focus on therapeutics investing.
• Walbert is managing partner of HRZN Partners, senior advisor to Amgen, former chairman, president, CEO of Horizon Therapeutics, which reached about USD 4 billion in annual sales before Amgen bought it for USD 28.3 billion in 2023.
• He previously led IDM Pharma through its sale to Takeda, held senior roles at Abbott, Merck, Wyeth, G.D. Searle.
• Walbert holds board seats across public and private health care companies, including Mirum Pharmaceuticals, Sagimet Biosciences, BioMarin Pharmaceutical.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Patient Square Capital LP published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.